Diseases of the liver Digestive System
Conditions
Interventions
Patients attending for their ‘annual year of care review’, ‘chronic disease review’ or ‘health check’ in primary care will be invited to participate in this study if they have risk factors for liver d
Fibroscan) and a metabolic assessment.
All participants will be given relevant lifestyle advice and an information booklet with advice on how to reduce their risk of liver disease progression.
We wi
Sponsors
Newcastle upon Tyne Hospitals NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Individuals aged 18-80 years attending for an ‘annual review of care’, ‘chronic disease review’ or ‘health check’ with one or more of the following risk factors for liver disease: 1. Obesity (BMI > 30), 2. Type 2 diabetes 3. Potentially harmful alcohol consumption (AUDIT score > 8) We have included an upper cut-off for the age of 80 for inclusion in this study. This is because liver disease generally has a slow progression to liver-related complications even with compensated cirrhosis, and as a result, asymptomatic individuals > 80 years are unlikely to benefit from early detection of liver disease.
Exclusion criteria
Exclusion criteria: 1. Life limiting disease on high risk or palliative care register 2. Known liver disease under secondary care follow up 3. Refusal or inability (lack of capacity) to provide informed consent 4. Unable to understand or speak English
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients identified with advanced liver fibrosis/cirrhosis using each of the pathways based on an overall clinical evaluation by a panel of hepatologists measured using study records at a single time point | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Usefulness of non-invasive testing/triage strategies to identify patients who have liver-related events (death, hepatic decompensation, transplantation) during longitudinal follow-up at 2, 5 and 10 years measured using electronic care records/NHS Digital 2. Performance of FIB-4, ELF, PRO-C3 and other novel blood-based biomarkers alone or in combination measured using overall clinical assessment or LSM to identify advanced fibrosis/cirrhosis at a single timepoint 3. Performance of the biomarkers to correctly exclude advanced fibrosis/cirrhosis as defined by overall clinical assessment or LSM at a single timepoint 4. Development of the optimum pathway (clinically and cost-effective and implementable) | — |
Countries
United Kingdom
Contacts
Public ContactLorna Brownlee
Outcome results
None listed